Goldman Sachs analyst Ziyi Chen downgraded Livzon (LVZPF) to Sell from Neutral with a price target of HK$22.99, down from HK$26.99. The firm expects near-term earnings pressure for Livzon due to policy impacts on its core products, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LVZPF:
- Livzon’s Psoriasis Biologic Lecankitug Enters China’s Priority Review Channel
- Livzon Pharmaceutical Trims Stake in Fluffy Buddy Through Connected Deemed Disposal
- Livzon Extends Deadline and Launches Tender Offer Plan for Vietnam’s Imexpharm
- Livzon Pharmaceutical Sets 2026 Caps on Connected Transactions With Livzon MAB
- Livzon Sets 2026 Caps for Connected Transactions With Controlling Shareholder Joincare